AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02936804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography
Description: LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
Study NCT00476853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART containing nevirapine
Description: Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
Study NCT02529969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Study NCT02529969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02019095 — intervention group
Intervention type: OTHER
Intervention: Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid
Study NCT02944487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsule for oral administration containing lucerastat
Study NCT02944487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT00105781 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise counseling
Study NCT04180761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
Study NCT02212782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg
Description: Linagliptin 5mg once daily for 7 days
Study NCT02212782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Linagliptin 5mg
Description: Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
Study NCT02094157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapered warfarin regimen
Description: This intervention is assigned to the experimental arm - Tapered warfarin regimen
Study NCT02094157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bridged regimen Low-molecular-weight heparin
Description: This intervention is assigned to the active control arm - Bridged regimen
Study NCT02267837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Patients carry out daily OrthoPulse™ treatments at home.
Study NCT02401789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)
Study NCT00395031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
Study NCT04431440 — intervention group
Intervention type: OTHER
Intervention: silver nanoparticles
Description: effect silver nanoparticles will be examined on multidrug resistant bacteria
Study NCT00645346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS glycoconjugate vaccine
Description: Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
Study NCT00645346 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one dose of placebo
Study NCT04078425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone Antagonists
Description: aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
Study NCT00787644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
Study NCT00787644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (inert tablet)
Study NCT00296621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: L-Glutamine
Study NCT00296621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03747861 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SenceBand
Description: Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
Study NCT04226196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an intraocular lens
Description: Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
Study NCT01704599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira Then Humira plus 3 B vitamins
Description: Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
Study NCT02885701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Splint
Description: The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.
Study NCT02885701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removable Splint
Description: The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
Study NCT02885701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-removable Splint
Description: The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
Study NCT00996398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tepid water immersion
Description: 28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
Study NCT01298986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation ablation procedure for atrial fibrillation
Description: The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
Study NCT01298986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid procedure for ablation of atrial fibrillation
Description: The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
Study NCT01298986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Cox Maze Procedure for Ablation of Atrial Fibrillation
Description: A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
Study NCT01298986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm
Description: The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
Study NCT03441321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle and Values Intervention
Description: Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
Study NCT03441321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Participate in Facebook group focusing on other health topics
Study NCT03441321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03441321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02516241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: IV infusion
Study NCT02516241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV infusion
Study NCT02516241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT02516241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03615196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: USB005 Ophthalmic Solution Placebo
Description: A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
Study NCT00117598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
Study NCT00117598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
Study NCT00117598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice
Description: Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day
Study NCT03869528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 sprays of 10% lignocaine
Description: 5 sprays of 10% lignocaine
Study NCT03869528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 sprays of 10% lignocaine
Description: 10 sprays of 10% lignocaine
Study NCT02501265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Standard Protocol
Description: 4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD
Study NCT02501265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch Standard Protocol
Description: 4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD
Study NCT02501265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Adaptive Protocol
Description: VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD
Study NCT02501265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Adaptive Protocol
Description: NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD
Study NCT04527302 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ERP combined with high-definition active tDCS
Description: The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4).
Study NCT04527302 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: ERP combined with sham tDCS
Description: Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
Study NCT02634853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tavilermide Ophthalmic Solution
Description: 1% Tavilermide BID Dosing
Study NCT02634853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Vehicle Ophthalmic Solution
Study NCT03681119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia symptom management at home hospice edition
Description: Quality assurance performance improvement program
Study NCT03681119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Training
Description: Education and training
Study NCT00356928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenously (IV) on Days -2 and -1.
Study NCT00356928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor T cells
Description: CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells
Study NCT03332563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for chronic pain
Description: WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
Study NCT02739607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic program
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
Study NCT01443104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)
Description: Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
Study NCT01443104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent with a durable polymer
Description: Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
Study NCT00872651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5%
Description: Travoprost 0.004%/Timolol 0.5%
Study NCT00872651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% / Timolol 0.5%
Description: Latanoprost 0.005% / Timolol 0.5%
Study NCT02942745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Nut Cessation Social Support
Description: The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
Study NCT02942745 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Betel Nut Cessation Booklet
Description: Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.